Harvey R, Ferrier D. Biochemistry (Lippincott Illustrated Reviews Series) (5th Edition). Lippincott Wiliams & Wikins, MD, USA (2010).
Murray R, Granner D, Mayes P, Rodwell V. Harper's Illustrated Biochemistry (26th Edition). The McGraw-Hill Companies, Inc., NY, USA (2003).
Koos R. Minireview: putting physiology back into estrogens' mechanism of action. Endocrinology 152 (12), 4481-4488 (2011).
Simpson R, Misso M, Hewitt N et al. Estrogen-the good, the bad, and the unexpected. Endocr. Rev. 26, 322-330 (2005).
Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Mechanisms of disease: production and actions of estrogens. N. Engl. J. Med. 346, 340-352 (2002).
Ferrucci L, Maggio M, Bandinelli S et al. Low Testosterone levels and the risk of anemia in older men and women. Arch. Intern. Med. 166, 1380-1388 (2006).
Snyder P, Peachey H, Berlin J et al. Effects of testosterone replacement in hypogonadal men. J. Clin. Endocrinol. Metab. 85, 2670-2677 (2000).
Burger H. How effective is testosterone replacement therapy in premenopausal women with severe androgen defciency? Nat. Clin. Pract. Endocrinol. Metab. 2, 432-433 (2006).
Nadkarni S, Cooper D, Brancaleone V, Bena S, Perretti M. Activation of the annexin A1 pathway underlies the protective effects exerted by estrogen in polymorphonuclear leukocytes. Arterioscler. Thromb. Vasc. Biol. 31, 2749-2759 (2011).
Rosano GM, Panina G. Oestrogens and the heart. Therapie 54, 381-385 (1999).
Carani C, Qin K, Simoni M et al. Effect of testosterone and estradiol in a man with aromatase defciency. N. Engl. J. Med. 337, 91-95 (1997).
Meethal SV, Liu T, Chan HW et al. Identifcation of a regulatory loop for the synthesis of neurosteroids: a steroidogenic acute regulatory protein-dependent mechanism involving hypothalamic-pituitary-gonadal axis receptors. J. Neurochem. 110, 1014-1027 (2009).
Lasiuk GC, Hegadoren KM. The effects of estradiol on central serotonergic systems and its relationship to mood in women. Biol. Res. Nurs. 9, 147-160 (2007).
Vlahopoulos S, Zimmer WE, Jenster G. Recruitment of the androgen receptor via serum response factor facilitates expression of a myogenic gene. J. Bio. Chem. 280, 7786-7792 (2005).
Zuloaga DG, Puts DA, Jordan CL, Breedlove SM. The role of androgen receptors in the masculinization of brain and behavior: what we've learned from the testicular feminization mutation. Horm. Behav. 53, 613-626 (2008).
Singh R, Artaza JN, Taylor WE et al. Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology 147, 141-154 (2006).
Burtis C, Ashwood E, Bruns D. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Elsevier Inc., MO, USA (2005).
Stocco D. Star protein and the regulation of steroid hormone biosynthesis. Annu. Rev. Physiol. 63, 193-213 (2001).
Miller W, Auchus R. The molecular biology biochemistry and physiology of human steroidogenesis and its disorders. Endocr. Rev. 32, 81-151 (2011).
Burger H. Androgen production in women. Fertil. Steril. 77, S3-S5 (2002).
Lukacik P, Kavanagh KL, Oppermann U. Structure and function of human 17beta-hydroxysteroid dehydrogenases. Mol. Cell. Endocrinol. 248, 61-71 (2006).
Mindnich R, Möller G, Adamski J. The role of 17 beta-hydroxysteroid dehydrogenases. Mol. Cell. Endo. 218, 7-20 (2004).
Peltoketo H, Luu-The V, Simard J, Adamski J. 17-Hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family, nomenclature and main characteristics of the 17HSD/KSR enzymes. J. Mol. Endocrinol. 23, 1-11 (1999).
Wu L, Einstein M, Geissler WM, Chan HK, Elliston KO, Andersson S. Expression cloning and characterization of human 17 beta-hydroxysteroid dehydrogenase type 2 a microsomal enzyme possessing 20 alpha-hydroxysteroid dehydrogenase activity. J. Biol. Chem. 268, 12964-12969 (1993).
Manolagas SC. Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 21, 115-137 (2000).
Marcus R. Agents affecting calcifcation and bone turnover. In: Goodman and Gilman's Pharmacological Basis of Therapeutics. McGraw-Hill, NY, USA 1519-1545 (1995).
Nijweidi Peter J, Feyen JH. Cells of bone: proliferation, differentiation, and hormonal regulation. Physiol. Rev. 66(4), 855-886 (1986).
Teitelbaum SL. Bone resorption by osteoclasts. Science 289, 1504-1508 (2000).
Murthy R, Morrow P, Theriault R. Bone biology and the role of the rank ligand pathway. Oncology 23, 9-15 (2009).
Albright F, Smith P, Richardson A. Postmenopausal osteoporosis: its clinical features. JAMA 116, 2465-2474 (1941).
Carruba G1, Adamski J, Calabrò M et al. Molecular expression of 17β hydroxysteroid dehydrogenase types in relation to their activity in intact human prostate cancer cells. Mol. Cell. Endocrinol. 131, 51-57 (1997).
Cassey ML, MacDonald PC, Andersson S. 17 beta-Hydroxysteroid dehydrogenase type 2: chromosomal assignment and progestin regulation of gene expression in human endometrium. J. Clin. Invest. 94, 2135-2141 (1994).
Miettinen MM, Mustonen MVJ, Poutanen MH, Isomaa VV, Vihko RK. Human 17β-hydroxysteroid dehydrogenase type 1 and type 2 isoenzymes have opposite activities in cultured cells and characteristic cell-and tissue-specifc expression. Biochem. J. 314, 839-845 (1995).
Mustonen M, Poutanen M, Chotteau-Lelievre A et al. Ontogeny of 17β-hydroxysteroid dehydrogenase type 2 mRNA expression in the developing mouse placenta and fetus. Mol. Cell. Endocrinol. 134, 33-40 (1997).
Mustonen MVJ, Poutanen MH, Kellokumpu S et al. Mouse 17 beta-hydroxysteroid dehydrogenase type 2 mRNA is predominantly expressed in hepatocytes and in surface epithelial cells of the gastrointestinal and urinary tracts. J. Mol. Endocrinol. 20, 67-74 (1998).
Cheng YH, Imir A, Fenkci V, Yilmaz MB, Bulun SE. Stromal cells of endometriosis fail to produce paracrine factors that induce epithelial 17beta-hydroxysteroid dehydrogenase type 2 gene and its transcriptional regulator Sp1: a mechanism for defective estradiol metabolism. Am. J. Obstet. Gynecol. 196, 391.e1-7 (2007).
Yang S, Fang Z, Gurates B. Stromal progesterone receptors mediate induction of 17beta-hydroxysteroid dehydrogenase type 2 expression in human endometrial epithelium: a paracrine mechanism for inactivation of E2. Mol. Endocrinol. 15, 2093-2105 (2001).
Day JM, Tutill HJ, Newman SP et al. 17Beta-hydroxysteroid dehydrogenase type 1 and type 2: association between mRNA expression and activity in cell lines. Mol. Cell. Endocrinol. 248, 246-249 (2006).
Cheng YH, Yin P, Xue Q, Yilmaz B, Dawson MI, Bulun SE. Retinoic acid (RA) regulates 17beta-hydroxysteroid dehydrogenase type 2 expression in endometrium: interaction of RA receptors with specifcity protein (SP) 1/SP3 for estradiol metabolism. J. Clin. Endocrinol Metab. 93, 1915-1923 (2008).
Zhongyi S, Rantakari P, Lamminen T, Toppari J, Poutanen M. Transgenic male mice expressing human hydroxysteroid dehydrogenase 2 indicate a role for the enzyme independent of its action on sex steroids. Endocrinology 148, 3827-3836 (2007).
Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Molecular Biology of the Cell (5th Edition). Garland Science, NY, USA (2007).
Thiboutot D, Martin P, Volikos L, Gilliland L. Oxidative activity of the type 2 isozyme of 17β-hydroxysteroid dehydrogenase (17β-HSD) predominates in human sebaceous glands. J. Invest. Dermatol. 111, 390-395 (1998).
Sonnhammer E L, von Heijne G, Krogh A. A hidden Markov model for predicting transmembrane helices in protein sequences. Proc. Int. Conf. Intell. Syst. Mol. Biol. 6, 175-182 (1998).
Casey ML, MacDonald PC, Andersson S. 17β-hydroxysteroid dehydrogenase type 2: chromosomal assignment and progestin regulation of gene expression in human endometrium. J. Clin. Invest. 94, 2135-2141 (1994).
Luu-The V. Analysis and characteristics of multiple types of human 17β-hydroxysteroid dehydrogenase. J. Steroid. Biochem. Mol. Biol. 67, 143-151 (2001).
Mutschler E, Schäfer-Korting M. Arzneimittelwirkungen (8th Edition). Wissenschaftliche Verlagsgesellschaft, Stuttgart, Germany (2001).
Delaforge M, Pruvost A, Perrin L, André F. Cytochrome P450-mediated oxidation of glucuronide derivatives: example of estradiol-17β-glucuronide oxidation to 2-hydroxy-estradiol-17β-glucuronide by CYP 2c8. Drug Metab. Dispos, 33(3), 466-473 (2004).
Lu ML, Huang Y W, Lin SX. Purifcation reconstitution and steady-state kinetics of the trans-membrane 17 beta-hydroxysteroid dehydrogena se 2. J. Biol. Chem. 277, 22123-22130 (2002).
Drolet R, Simard M, Plante J, Laberge P, Tremblay Y. Human type 217 beta-hydroxysteroid dehydrogenase mRNA and protein distribution in placental villi at mid and term pregnancy. Reprod. Biol. Endocrinol. 5, 30 (2007).
Mustonen M, Poutanen M, Chotteau-Lelievre A et al. Ontogeny of 17 β hydroxysteroid dehydrogenase type 2 mRNA expression in the developing mouse placenta and fetus. Mol. Cell. Endocrinol. 134, 33-40 (1997).
Simard M1, Plante J, Boucher M, Provost PR, Tremblay Y. Type 2 and 517beta-hydroxysteroid dehydrogenases and androgen receptor in human fetal lungs. Mol. Cell. Endocrinol. 319, 79-87 (2010).
Zeitoun K1, Takayama K, Sasano H et al. Defcient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol. J. Clin. Endocrinol Metab. 83, 4474-4480 (1998).
Noble LS, Simpson ER, Johns A, Bulun SE. Aromatase expression in endometriosis. J. Clin. Endocrinol. Metab. 81, 174-179 (1996).
Noble LS, Takayama K, Putman JM. Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells. J. Clin. Endocrinol. Metab. 82, 600-606 (1997).
Simpson ER, Zhao Y, Agarwal VR. Aromatase expression in healthand disease. Recent Prog. Horm. Res. 52, 185-214 (1997).
Bulun SE, Noble LS, Takayama K. Endocrine disorders associated with inappropriately high aromatase expression. J. Steroid. Biochem. Mol. Biol. 61, 133-139 (1997).
Ono YJ, Terai Y, Tanabe A et al. Decorin induced by progesterone plays a crucial role in suppressing endometriosis. J. Endocrinol. 223, 203-216 (2014).
Tamaresis JS, Irwin JC, Goldfen GA et al. Molecular classifcation of endometriosis and disease stage using high-dimensional genomic data. Endocrinology 155, 4986-4999 (2014).
Zito G, Luppi S, Giolo E et al. Medical treatments for endometriosis-associated pelvic pain. Biomed. Res. Int. 2014, 191967 (2014).
Shen F, Yan C, Liu M, Feng Y, Chen Y. Decreased expression of mucin-1 in endometriosis endometrium correlated with progesterone receptor B involved in infertility. Arch. Gynecol. Obstet. 291(2), 439-445 (2014).
Oliveira IO, Lhullier C, Brum IS, Spritzer PM. Gene expression of type 217 beta hydroxysteroid dehydrogenase in scalp hairs of hirsute women. Steroids 68, 641-649 (2003).
Rantakari P, Strauss L, Kiviranta R, Lagerbohm H, Paviala J, Holopainen I. Placenta defects and embryonic lethality resulting from disruption of mouse hydroxysteroid (17-beta) dehydrogenase 2 gene. Mol. Endocrinol. 22(3), 665-675 (2008).
Travis R, Key K. Oestrogen exposure and breast cancer risk. Breast Cancer Res. 5, 239-247 (2003).
Oduwole OO, Li Y, Isomaa VV et al. 17Beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer. Cancer Res. 64, 7604-7609 (2004).
Suzuki T, Moriya T, Ariga N, Kaneko C, Kanazawa M, Sasano H. 17Betahydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters. Br. J. Cancer 82, 518-523 (2000).
Gunnarsson C, Olsson BM, Stål O. Abnormal expression of 17betahydroxysteroid dehydrogenases in breast cancer predicts late recurrence. Cancer Res. 61, 8448-8451 (2001).
Gunnarsson C, Hellqvist E, Stål O. 17Beta-hydroxysteroid dehydrogenases involved in local oestrogen synthesis have prognostic signifcance in breast. Br. J. Cancer 92, 547-552 (2005).
Jansson A. 17Beta-hydroxysteroid dehydrogenase enzymes and breast cancer. J. Steroid Biochem. Mol. Biol. 114, 64-67 (2009).
Yaeger R, Nolan PC, Su T et al. 17 β HSD 2 may be higher in African-American breast cancer and is associated with estrogen receptor-negative tumors. Cancer Geno Prots. 4, 341-348 (2007).
Ito K, Utsunomiya H, Suzuki T et al. 17Beta-hydroxysteroid dehydrogenases in human endometrium and its disorders. Mol. Cell. Endocrinol. 248, 136-140 (2006).
Sasano H, Suzuki T, Niikura H et al. 17 beta-hydroxysteroid dehydrogenase in common epithelial ovarian tumors. Mod. Pathol. 9, 386-391 (1996).
Feix M, Wolf L, Schweikert HU. Distribution of 17β-hydroxysteroid dehydrogenases in human osteoblast-like cells. Mol. Cell. Endocrinol. 171, 163-164 (2001).
Du Z, Steck R, Doan N, Woodruff M, Ivanovski S, Xiao Y. Estrogen defciency associated bone loss in the maxilla: a methodology to quantify the changes in the maxillary intra-radicular alveolar bone in an ovariectomized rat osteoporosis model. Tissue. Eng. Part. C Methods 21(5), 458-466 (2014).
Van Caenegem E, Wierckx K, Taes Y et al. Preservation of volumetric bone density and geometry in trans women during cross-sex hormonal therapy: a prospective observational study. Osteoporos. Int. 26, 35-47 (2015).
Ward KA, Roberts SA, Adams JE, Mughal MZ. Bone geometry and density in the skeleton of pre-pubertal gymnasts and school children. Bone 36, 1012-1018 (2005).
McCarthy TL, Centrella M. Prostaglandin dependent control of an endogenous estrogen receptor agonist by osteoblasts. J. Cell. Physiol. 230, 1104-14 (2015).
Swift SN, Swift JM, Bloomfeld SA. Mechanical loading increases detection of estrogen receptor-alpha in osteocytes and osteoblasts despite chronic energy restriction. J. Appl. Physiol. 117, 1349-1355 (2014).
Gourlay M, Richy F, Reginster J. Strategies for the prevention of hip fracture. Am. J. Med. 115, 309-317 (2003).
Body J. How to manage postmenopausal osteoporosis? Acta Clin. Belg, 66(6), 443-447 (2011).
Wells GA, Cranney A, Peterson J et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst. Rev. 23(1), CD001155 (2008).
Lin J, Lane J. Osteoporosis: a review. Clin. Orthop. 425, 126-134 (2004).
Yates J, Barrett-Connor E, Barlas S et al. Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. Obstet. Gynecol. 103(3), 440-446 (2004).
Delmas P. Treatment of postmenopausal osteoporosis. Lancet 359, 2018-2026 (2002).
Grobbee D. LIFT study to continue as planned. BMJ 331, 843 (2005).
Reginster J. Prevention of postmenopausal osteoporosis with pharmacological therapy: practice and possibilities. J. Intern. Med. 255, 615-628 (2004).
WHO. Prevention and management of osteoporosis. WHO Tech. Rep. Ser. 92, 1-164 (2003).
Åkesson K. New approaches to pharmacological treatment of osteoporosis. Bull. WHO 81, 657-664 (2003).
Sambrook PN, Seeman E, Phillips SR et al. Preventing osteoporosis: outcomes of the Australian Fracture Prevention Summit. Med. J. Aust. 176, S1-S16 (2002).
Rosen C, Bilezikian J. Clinical review 123: Hot Topic: anabolic therapy for osteoporosis. J. Clin. Endocrinol. Metab. 86(3), 957-964 (2001).
Adams J, Pepping J. Vitamin K in the treatment and prevention of osteoporosis and arterial calcifcation. Am. J. Health-Syst. Pharm. 62, 1574-1581 (2005).
McClung M, Lewiecki M, Cohen S et al. Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 354, 821-831 (2006).
Bagi CM, Wood J, Wilkie D, Dixon B. Effect of 17p-hydroxysteroid dehydrogenase type 2 inhibitor on bone strength in ovariectomized cynomolgus monkeys. J. Musculoskelet. Neuronal. Interact. 8, 267-280 (2008).
Puranen TJ, Kurkela RM, Lakkakorpi JT. Characterization of molecular and catalytic properties of intact and truncated human 17p-hydroxysteroid dehydrogenase type 2 enzymes: intracellular localization of the wild-type enzyme in the endoplasmic reticulum. Endocrinology 140, 3334-3341 (1999).
Luu-The V, Zhang Y, Poirier D, Labrie F. Characteristics of human types 12 and 317p-hydroxy steroid dehydrogenase activities: oxidation/re duction and inhibition. J. Steroid Biochem. Mol. Biol. 55, 581-587 (1995).
Zhu BT, Han GZ, Shim JY, Wen Y, Jiang XR. Quantitative structure-activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: insights into the structural determinants favoring a differential subtype binding. Endocrinology 147, 4132-4150 (2006).
Qiu W, Campbell RL, Gangloff A et al. A concerted rational design of type 117beta-hydroxysteroid dehydrogenase inhibitors: estradiol-adenosine hybrids with high affnity FASEB J. 16, 1829-1831 (2002).
Wood J, Bagi C, Akuche C et al. 45-Disubstituted cis-pyrrolidinones as inhibitors of type II 17p-hydroxysteroid dehydrogenase. Part 3. Identifcation of lead candidate. Bioorg Med. Chem. Lett. 16, 4965-4968 (2006).
Knittel J, Zavod R. Drug design and relationship of functional groups to pharmacologic activity. In: Foye's Principles of Medicinal Chemistry (6th Edition). Lippincott Williams & Wilkins, NY, USA, 26-52 (2008).
Deluca D, Krazeisen A, Breitling R, Prehn C, Möller G, Adamski J. Inhibition of 17beta-hydroxysteroid dehydrogenases by phytoestrogens: Comparison with other steroid metabolizing enzymes. J. Steroid Biochem. Mol. Biol. 93, 285-292 (2005).
Le Bail JC, Champavier Y, Chulia AJ, Habrioux G. Effects of phytoestrogens on aromatase 3 beta and 17beta-hydroxysteroid dehydrogenase activities and human breast cancer cells. Life Sci. 66, 1281-1291 (2000).
Le Bail JC, Laroche T, Marre-Fournier F, Habrioux G. Aromatase and 17beta-hydroxysteroid dehydrogenase inhibition by favonoids. Cancer Lett. 133, 101-106 (1998).
Auger S, Luu-The V, Mane Sam K, Poirier D. 3-Hydroxy-19-nor-17ct-pregna-135(10)-triene-2117p-carbolactone as inhibitor of 17p-hydroxysteroid dehydrogenase type 2. Bioorg. Med. Chem. Lett. 4, 2045-2048 (1994).
Sam KM, Auger S, Luu-The V, Poirier D. Steroidal Spiro-. gamma.-lactones that inhibit 17.beta.-hydroxysteroid dehydrogenase activity in human placental microsomes. J. Med. Chem. 38, 4518-4528 (1995).
Poirier D, Bydal P, Tremblay M, Luu-The V. Inhibitors of type II 17p-hydroxysteroid dehydrogenase, Mol. Cell. Endocrinol. 171(1-2), 119-128 (2001).
Bydal P, Auger S, Poirier D. Inhibition of type 217beta-hydroxysteroid dehydrogenase by estradiol derivatives bearing a lactone on the D-ring: structure-activity relationships. Steroids 69, 325-342 (2004).
Sam KM, Labrie F, Poirier D. N-Butyl-N-methyl-11-(3'-hydroxy-21' 17'-carbolactone-19'-nor-17 'ct-pregna-1' 3' 5'(10')-trien-7'ct-yl)-undecanamide: an inhibitor of type 217p-hydroxysteroid dehydrogenase that does not have oestrogenic or androgenic activity. Eur. J. Med. Chem. 35, 217-225 (2000).
Xu K, Wetzel M, Hartmann R, Marchais-Oberwinkler S. Spiro-5-lactones as Inhibitors of 17p-hydroxysteroid dehydrogenase type 2 (17p-HSD2). Lett. Drug Des. Disc. 8, 406-421 (2011).
Hoffmann M, Rychlewski J. When, in the context of drug design, can a fuorine atom successfully substitute a hydroxyl group? Int. J. Quantum Chem. 48(4), 419-427 (2002).
Deluca D, Möller G, Rosinus A, Elger W, Hillisch A, Adamski J. Inhibitory effects of fuorine-substituted estrogens on the activity of 17beta-hydroxysteroid dehydrogenases. Mol. Cell. Endocrinol. 248, 218-224 (2006).
Cook J, Barzya J, Brennan C et al. 45-disubstituted cis-pyrrolidinones as inhibitors of 17p-hydroxysteroid dehydrogenase II. Part 1: synthetic approach. Tetrahed. Lett. 46, 1525-1528 (2005).
Gunn D, Akuche C, Baryza J et al. 45-disubstituted cis-pyrrolidinones as inhibitors of type II 17p-hydroxysteroid dehydrogenase. Part 2. SAR. Bioorg. Med. Chem. Lett. 15, 3053-3057 (2005).
Bey E, Marchais-Oberwinkler S, Kruchten P et al. Design synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases. Bioorg. Med. Chem. 16, 6423-6435 (2008).
Al-Soud Y, Bey E, Oster A et al. The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17p-hydroxysteroid dehydrogenase (17p-HSD) type 1 and type 2. Mol. Cell. Endocrinol. 301, 212-215 (2009).
Bey E, Marchais-Oberwinkler S, Kruchten P et al. New Insights into the SAR and binding modes of Bis(hydroxyphenyl)thiophenes and-benzenes: influence of additional substituents on 17p-hydroxysteroid dehydrogenase type 1 (17p-HSD1) inhibitory activity and selectivity. J. Med. Chem. 52, 6724-6743 (2009).
Al-Soud YA, Marchais-Oberwinkler S, Frotscher M, Hartmann RW. Synthesis and biological evaluation of phenyl substituted 1H-124-triazoles as non-steroidal inhibitors of 17p-hydroxysteroid dehydrogenase type 2. Arch. Pharm. (Weinheim) 345, 610-621 (2012).
Xu K, Al-Soud YA, Wetzel M, Hartmann RW, Marchais-Oberwinkler S. Triazole ring-opening leads to the discovery of potent nonsteroidal 17p-hydroxysteroid dehydrogenase type 2 inhibitors. Eur. J. Med. Chem. 46, 5978-5990 (2011).
Marras G, Metrangolo P, Meyer F, Pilati T, Resnat G, Vij A. Solid state synthesis under supramolecular control of a 2D heterotetratopic self-complementary tecton tailored to halogen bonding. New Journal of Chemistry 30, 1397-1402 (2006).
Marchais-Oberwinkler S, Xu K, Wetzel M et al. Structural optimization of 2, 5-thiophene amides as highly potent and selective 17p-hydroxysteroid dehydrogenase type 2 inhibitors for the treatment of osteoporosis, J. Med. Chem, 56(1), 167-181 (2013).
Perspicace E, Cozzoli L, Gargano EM et al. Novel potent and selective 17p-hydroxysteroid dehydrogenase type 2 inhibitors as potential therapeutics for osteoporosis with dual human and mouse activities. Eur. J. Med. Chem. 83, 317-337 (2014).
Gargano EM, Perspicace E, Hanke N, Carotti A, Marchais-Oberwinkler S, Hartmann RW. Metabolic stability optimization and metabolite identifcation of 25-thiophene amide 17p-hydroxysteroid dehydrogenase type 2 inhibitors. Eur. J. Med. Chem. 87C, 203-219 (2014).
Wetzel M, Gargano EM, Hinsberger S, Marchais-Oberwinkler S, Hartmann RW. Discovery of a new class of bicyclic substituted hydroxyphenylmethanones as 17p-hydroxysteroid dehydrogenase type 2 (17p-HSD2) inhibitors for the treatment of osteoporosis. Eur. J. Med. Chem. 47, 1-17 (2012).
Oster A, Hinsberger S, Werth R, Marchais-Oberwinkler S, Frotscher M, Hartmann RW. Bicyclic substituted hydroxyphenylmethanones as novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases. J. Med. Chem. 53, 8176-8186 (2010).
Oster A, Klein T, Henn C et al. Bicyclic substituted hydroxyphenylmethanones as novel inhibitors of 17p-hydroxysteroid dehydrogenase type 1 (17p-HSD1) for the treatment of estrogen-dependent diseases. Chem. Med. Chem. 6, 476-487 (2011).
Perspicace E, Giorgio A, Carotti A, Marchais-Oberwinkler S, Hartmann RW. Novel N-methylsulfonamide and retro-N-methylsulfonamide derivatives as 17p-hydroxysteroid dehydrogenase type 2 (17p-HSD2) inhibitors with good ADME-related physicochemical parameters. Eur. J. Med. Chem. 69, 201-215 (2013).
Frotscher M, Ziegler E, Marchais-Oberwinkler S et al. Design synthesis and biological evaluation of (Hydroxyphenyl)naphtalene and-quinoline derivatives: potent and selective nonsteroidal inhibitors of 17p-hydroxysteroid dehydrogenase type 1 (17p-HSD1) for the treatment of estrogen-dependent diseases. J. Med. Chem. 51, 2158-2169 (2008).
Wetzel M, Marchais-Oberwinkler S, Hartmann RW. 17p-HSD2 inhibitors for the treatment of osteoporosis: Identifcation of a promising scaffold. Bioorg. Med. Chem. 19, 807-815 (2011).
Wetzel M, Marchais-Oberwinkler S, Perspicace E, Möller G, Adamski J, Hartmann RW. Introduction of an electron withdrawing group on the hydroxyphenylnaphtol scaffold improves the potency of 17p-hydroxysteroid dehydrogenase type 2 (17p-HSD2) inhibitors. J. Med. Chem. 54, 7547-7557 (2011).
Vuorinen A, Engeli R, Meyer A et al. Ligand-based pharmacophore modeling and virtual screening for the discovery of novel 17p-hydroxysteroid dehydrogenase2 inhibitors. J. Med. Chem. 57, 5995-6007 (2014).
Papapoulos S. Inhibition of sclerostin in the management of osteoporosis: results of a Phase 2 clinical trial meet expectations. Bonekey Rep. 3, 523 (2014).
Negishi-Koga T, Shinohara M, Komatsu N et al. Suppression of bone formation by osteoclastic expression of semaphorin 4D. J. Nat. Med. 17(11), 1473-1480 (2011).
Zhang Y, Wei L, Miron R, Zhang Q, Bian Z. Prevention of alveolar bone loss in an osteoporotic animal model via interference of semaphorin 4d. J. Dent. Res. 93(11), 1095-1100 (2014).
Hamdy NA. Osteoprotegerin as a potential therapy for osteoporosis. Curr. Osteoporos. Rep. 3(4), 121-125 (2005).
